BACKGROUND: Amine catabolism by monoamine oxidase A (MAOA) contributes to oxidative stress, which plays a role in prostate cancer (PCa) development and progression. An upstream variable-number tandem repeat (uVNTR) in the MAOA promoter influences gene expression and activity, and may thereby affect PCa susceptibility. METHODS: Caucasian (n = 2,572) men from two population-based case-control studies of PCa were genotyped for the MAOA-VNTR. Logistic regression was used to assess PCa risk in relation to genotype. RESULTS: Common alleles of the MAOA-VNTR were not associated with the relative risk of PCa, nor did the relationship differ by clinical features of the disease. The rare 5-copy variant (frequency: 0.5% in cases; 1.8% in controls), however, was associated with a reduced PCa risk (odds ratio, OR = 0.30, 95% CI 0.13-0.71). CONCLUSIONS: A rare polymorphism of the MAOA promoter previously shown to confer low expression was associated with a reduced risk of developing PCa. This novel finding awaits confirmation in other study populations.
BACKGROUND:Amine catabolism by monoamine oxidase A (MAOA) contributes to oxidative stress, which plays a role in prostate cancer (PCa) development and progression. An upstream variable-number tandem repeat (uVNTR) in the MAOA promoter influences gene expression and activity, and may thereby affect PCa susceptibility. METHODS: Caucasian (n = 2,572) men from two population-based case-control studies of PCa were genotyped for the MAOA-VNTR. Logistic regression was used to assess PCa risk in relation to genotype. RESULTS: Common alleles of the MAOA-VNTR were not associated with the relative risk of PCa, nor did the relationship differ by clinical features of the disease. The rare 5-copy variant (frequency: 0.5% in cases; 1.8% in controls), however, was associated with a reduced PCa risk (odds ratio, OR = 0.30, 95% CI 0.13-0.71). CONCLUSIONS: A rare polymorphism of the MAOA promoter previously shown to confer low expression was associated with a reduced risk of developing PCa. This novel finding awaits confirmation in other study populations.
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Lawrence True; Ilsa Coleman; Sarah Hawley; Ching-Ying Huang; David Gifford; Roger Coleman; Tomasz M Beer; Edward Gelmann; Milton Datta; Elahe Mostaghel; Beatrice Knudsen; Paul Lange; Robert Vessella; Daniel Lin; Leroy Hood; Peter S Nelson Journal: Proc Natl Acad Sci U S A Date: 2006-07-07 Impact factor: 11.205
Authors: Robert A Philibert; Pamela Wernett; Jeff Plume; Hans Packer; Gene H Brody; Steven R H Beach Journal: Biol Psychol Date: 2011-05-07 Impact factor: 3.251
Authors: Robert A Philibert; Tracy D Gunter; Steven R H Beach; Gene H Brody; Anup Madan Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-07-05 Impact factor: 3.568
Authors: William F Maragos; Kristie L Young; Chris S Altman; Chava B Pocernich; Jennifer Drake; D Allan Butterfield; Isabelle Seif; Daniel P Holschneider; Kevin Chen; Jean C Shih Journal: Neurochem Res Date: 2004-04 Impact factor: 3.996
Authors: Scott R Bauer; Erin L Richman; Eduardo Sosa; Vivian Weinberg; Xiaoling Song; John S Witte; Peter R Carroll; June M Chan Journal: Prostate Date: 2013-08-29 Impact factor: 4.104
Authors: Gennady M Zharinov; Sergei E Khalchitsky; Alexandre Loktionov; Marina V Sogoyan; Yulia V Khutoryanskaya; Natalia Yu Neklasova; Oleg A Bogomolov; Ilya V Smirnov; Marina P Samoilovich; Vladimir N Skakun; Sergei V Vissarionov; Vladimir N Anisimov Journal: Oncotarget Date: 2021-03-30